Wall Street Zen upgraded shares of Beneficient (NASDAQ:BENF – Free Report) to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Beneficient in a report on Monday, September 21st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Beneficient currently has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on Beneficient
Beneficient Trading Down 1.5%
BENF stock opened at $0.79 on Friday. Beneficient has a fifty-two week low of $0.50 and a fifty-two week high of $9.96. The business’s 50 day moving average price is $1.48 and its two-hundred day moving average price is $3.17.
Beneficient (NASDAQ:BENF – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $1.59. The business had revenue of $15.93 million during the quarter, compared to the consensus estimate of $10.16 million. Equities research analysts anticipate that Beneficient will post -9.50 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Beneficient
A hedge fund recently bought a new position in Beneficient stock. T3 Companies LLC purchased a new stake in shares of Beneficient (NASDAQ:BENF – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 43,030 shares of the company’s stock, valued at approximately $59,000. T3 Companies LLC owned approximately 0.28% of Beneficient at the end of the most recent reporting period. 90.57% of the stock is currently owned by hedge funds and other institutional investors.
About Beneficient
Beneficient (NASDAQ: BENF) is a financial services company that provides liquidity and trust-based solutions for holders of alternative assets. Its platform is designed to help investors access cash from illiquid investments, including private equity, venture capital, real estate, private credit and other privately held assets, without necessarily waiting for those investments to reach maturity or a traditional exit.
The company serves individuals, families, trusts, family offices and certain institutional investors.
Further Reading
- Five stocks we like better than Beneficient
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Beneficient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beneficient and related companies with MarketBeat.com's FREE daily email newsletter.
